Treatment of Myelodysplastic Syndrome with Symptomatic Neutropaenia in Lower-Risk Disease (IPSS-R up to 3.5)
This page covers the management approach for patients with lower-risk myelodysplastic syndrome (IPSS-R up to 3.5) who present with symptomatic neutropaenia — a specific clinical situation with distinct treatment considerations.
For therapeutic purposes, the term lower-risk MDS applies to cases with an IPSS-R score up to 3.5, encompassing very low- and low-risk, and part of the intermediate-risk IPSS-R group. Within this population, symptomatic neutropaenia represents a clinically significant complication that drives a targeted management strategy.
The approach to symptomatic neutropaenia in lower-risk MDS involves early antimicrobial measures triggered by specific clinical signs, alongside the potential use of a haematopoietic growth factor. Further options may be considered based on individual patient features and applicable regulatory approvals. The complete sequence, criteria, and full list of options are set out in the structured protocol.
Improvement of neutropaenia.
- For therapeutic purposes, the term 'lower-risk' MDS generally applies to cases with IPSS-R up to 3.5 including very low- and low-risk and part of intermediate-risk IPSS-R patients.
- Symptomatic neutropaenia
- Prophylactic antibiotics and/or G-CSF are not recommended in case of neutropaenia, but rapid onset of broad-spectrum antibiotics is mandatory in case of fever or symptoms of infection [II, A].
- G-CSF can improve neutropaenia in 60%–75% of these cases and can be added to anti-infective drugs [III, C], but its prolonged use has not demonstrated any impact on survival.
- Short-term use of G-CSF during severe infections could be useful in neutropaenic patients.